Mounjaro clinical trials for obesity: a doctor explains the latest evidence and weight-loss effects

  • Published:
  • Updated:
  • Written by the Hiro Clinic Medical Weight Loss editorial team
  • 50 min read
Medically reviewed by Dr. Hiroko Oka Reviewed byDr. Hiroko OkaCertified Member, Japanese Society of Internal Medicine Editorial policy
Mounjaro clinical trials for obesity: a doctor explains the latest evidence and weight-loss effects

Key points firstShort on time? Just read this part

  • The weight-loss effect of Mounjaro has been tested in an international clinical trial program called the SURMOUNT trial series
  • The side effects of Mounjaro reported in clinical trials are mainly gastrointestinal symptoms; most appear early in treatment and tend to ease over time
  • At present, data are still limited on Mounjaro’s long-term effect on reducing cardiovascular risk and on mortality

What you will learn in this article

  • How Mounjaro works
  • Weight-loss effects reported in international clinical trials (the SURMOUNT trial series)
  • Possible side effects
  • How it differs from existing obesity medications
  • How it is given in practice
  • Precautions for using it safely

Please also note that using Mounjaro for weight loss is self-pay treatment (not covered by health insurance; you pay the full cost), and that effects and side effects vary from person to person.

Introduction

Mounjaro (generic name: tirzepatide) is a once-weekly subcutaneous injection classified as a GIP/GLP-1 receptor dual agonist, and international clinical trials have confirmed strong weight-loss effects. Obesity is a global public health issue that raises the risk of many health problems, including lifestyle-related diseases, cardiovascular disease and diabetes, and the number of people with obesity is rising in Japan and abroad. As medical intervention for weight management becomes more important, Mounjaro has attracted attention in recent years. In this article, we focus on the results of Mounjaro’s clinical trials and explain its effectiveness and safety and its place in obesity treatment.

What is Mounjaro?

Mounjaro is a medication that acts on the receptors for both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), given as a once-weekly self-injection (subcutaneous injection). GLP-1 and GIP are both hormones released from the intestines after meals, and they contribute to weight loss and blood sugar control by suppressing appetite, adjusting how fast the stomach empties and promoting insulin secretion. Mounjaro is characterized as a “dual receptor agonist” that acts on both receptors at the same time, and clinical trials have confirmed stronger weight-loss effects than with conventional drugs that act only on GLP-1.

When talking with patients during consultations, we sometimes meet people who say, “I thought Mounjaro was a pill.” In fact, it is a medication you inject yourself once a week into the abdomen, thigh or upper arm, using a prefilled injection pen. The needle is very fine and designed to cause little pain, but some people feel uneasy about injections themselves, so for the first time, a doctor or nurse carefully explains the technique before you begin.

Weight loss with Mounjaro in clinical trials

The weight-loss effect of Mounjaro has been tested in an international clinical trial program called the SURMOUNT trial series. Efficacy and safety have been confirmed in several groups, ranging from patients with type 2 diabetes without obesity to adults with obesity or overweight who do not have diabetes.

Weight loss in the SURMOUNT-1 trial

The SURMOUNT-1 trial is a representative trial showing Mounjaro’s weight-loss effect. In adults with obesity or overweight who did not have diabetes, Mounjaro was given for 72 weeks, and significantly greater weight loss compared with the placebo group was reported (Jastreboff AM, et al. N Engl J Med, 2022). Higher-dose groups tended to lose more weight, and in the highest-dose group, an average loss of around 20% of body weight was reported. Note that these figures were obtained on top of lifestyle-improvement guidance and are not effects achieved with Mounjaro alone.

Effects in patients with type 2 diabetes (SURMOUNT-2 trial)

The SURMOUNT-2 trial studied patients with obesity or overweight who had type 2 diabetes. In the Mounjaro group, improvement in HbA1c (an indicator reflecting average blood sugar over the past 1–2 months) was seen in addition to weight loss, suggesting it may contribute not only to obesity treatment but also to improved glucose metabolism. For patients who also have diabetes, being able to aim for weight management and blood sugar control at the same time is highly significant.

Differences in effect by dose

Mounjaro is started at a low dose (2.5 mg) and increased every few weeks while checking for side effects such as gastrointestinal symptoms. The SURMOUNT trial series compared weight loss at doses such as 5 mg, 10 mg and 15 mg, and found that higher doses tended to produce greater average weight loss. However, the pace of dose escalation and the dose that can be reached vary from person to person, so the doctor adjusts them based on the severity of gastrointestinal symptoms and your physical condition.

How Mounjaro works

By acting on both the GIP receptor and the GLP-1 receptor, Mounjaro has stronger appetite-suppressing and blood sugar-improving effects than drugs that act on a single receptor. Its main actions are as follows.

  1. Appetite suppression
    It acts on GLP-1 and GIP receptors and sends signals to the feeding center in the hypothalamus, suppressing appetite.
  2. Slower stomach emptying
    By slowing stomach emptying, it keeps you feeling full for longer and helps prevent overeating.
  3. Promoting insulin secretion and improving blood sugar
    It promotes insulin secretion in response to the rise in blood sugar after eating, curbing sharp spikes in blood sugar. Its action on the GIP receptor is also thought to be involved in improving insulin sensitivity in fat tissue.

Mounjaro’s strength is that the combination of these actions makes it easier to achieve sustained weight loss that is hard to reach with calorie restriction alone. However, the drug’s action only supports lifestyle improvements such as diet and exercise, and relying on the drug alone without reviewing your lifestyle is not recommended.

Safety and side effects

The side effects of Mounjaro reported in clinical trials are mainly gastrointestinal symptoms; most appear early in treatment and tend to ease over time. Specifically, these include nausea, diarrhea, constipation and abdominal bloating. Pancreatitis has been reported as a serious adverse reaction, but it is considered rare. In addition, few clear cardiovascular adverse events have been reported so far, and its safety is assessed as relatively good. Local reactions such as redness or itching at the injection site may occur, but most are mild and improve on their own.

Mounjaro compared with existing obesity medications

A major difference between Mounjaro and conventional obesity medications is that it combines appetite suppression and blood sugar improvement via GIP/GLP-1 receptors. Conventional obesity medications include orlistat, which reduces fat absorption; the naltrexone/bupropion combination, which acts on the central nervous system; and drugs that act only on the GLP-1 receptor. These differ in mechanism and how they are given, promoting weight loss by reducing fat absorption or acting on the central nervous system, whereas Mounjaro is considered to have a broader range of action because it activates two receptors at the same time. Especially for patients with type 2 diabetes, it can be one option because it allows aiming for both blood sugar control and weight loss at the same time.

Potential clinical uses of Mounjaro

Uses of Mounjaro are being studied in a wide range of people, from patients with general obesity to those who also have diabetes. The main directions for clinical use are the following three.

  1. Use in patients with general obesity
    For patients with a BMI of 30 or higher, or a BMI of 27 or higher with obesity-related conditions, Mounjaro can be one option for weight management. It is considered especially when lifestyle improvements alone are not effective enough.
  2. Use in patients with diabetes
    Because it may help achieve both weight loss and blood sugar improvement, its use is also being considered for patients with type 2 diabetes who have obesity.
  3. Support for weight loss before surgery
    It may also be used for weight loss before obesity surgery or for weight management before medical interventions, and it may help reduce surgical risk.

Mounjaro’s approval status in Japan and how to use it correctly: a guide to the latest medical weight loss

Bottom line firstShort on time? Just read thisIn Japan, Mounjaro is approved ...

How it is given in practice and precautions

Mounjaro is a medication you self-inject once a week with an injection pen, and it can be given regardless of meal timing. Because gastrointestinal symptoms are common early in treatment, the usual schedule starts at a low dose (2.5 mg) and increases gradually every few weeks. Rotating the injection site among the abdomen, thigh and upper arm helps reduce local reactions. In addition, careful use is needed if you have a history of kidney impairment or pancreatic disease, and a prior medical interview and regular follow-up are essential.

Not sure if it suits you? Start with a consultation.

A doctor decides whether you can use it and which dose is appropriate, based on your consultation and questionnaire.

No consultation fee (first & follow-up visits)Online consultation available

Limitations of the current evidence

At present, data are still limited on Mounjaro’s long-term effect on reducing cardiovascular risk and on mortality. The SURMOUNT trial series focused mainly on efficacy and safety, and data examining long-term outcomes over a decade or more are still being collected. In addition, large-scale data on Asian people, including Japanese people, are limited compared with Western populations, so building up clinical data in Japan remains a future task.

Lifestyle tips to enhance Mounjaro’s clinical effects

Mounjaro alone has shown weight-loss effects, but combining it with lifestyle improvements may lead to more stable weight loss. Specific points include the following.

  1. Diet management
    Limit high-fat, high-sugar foods and aim for a well-balanced diet centered on vegetables and protein. Because Mounjaro suppresses appetite, it helps as an aid to prevent overeating.
  2. Regular exercise
    Combining aerobic exercise and strength training helps maintain or raise basal metabolism and promotes loss of body fat. In clinical trials as well, greater weight loss has been reported in groups that received lifestyle guidance together with the drug.
  3. Better sleep quality
    Lack of sleep disturbs the balance of appetite hormones and raises the risk of overeating. Getting enough sleep makes it easier to get the most out of Mounjaro’s appetite-suppressing effect.
Woman sleeping

Guidelines on the use of Mounjaro in Japan and abroad

In the United States, GIP/GLP-1 receptor agonists are widely used for patients with obesity or obesity-related complications, and in Japan, use is expanding following its approval as a treatment for type 2 diabetes. In guidelines related to the American Diabetes Association (ADA) and the American Society for Metabolic and Bariatric Surgery (ASMBS), GLP-1 and GIP receptor agonists are positioned as an option for patients with a BMI of 30 or higher, or a BMI of 27 or higher with obesity-related complications. They are valued especially in patients with type 2 diabetes because they allow aiming for both weight loss and blood sugar improvement at the same time.

In Japan, Mounjaro was approved in 2023 as a treatment for type 2 diabetes, and when prescribed for diabetes treatment it may be covered by health insurance. On the other hand, use for treating obesity without diabetes is not covered by health insurance and is prescribed as self-pay treatment. Clinics offering medical weight loss, including ours, prescribe Mounjaro as self-pay treatment after a doctor’s consultation, as one option for patients who find lifestyle improvements difficult. It is hoped that, as clinical data on Japanese people accumulate, its place in obesity treatment will become even clearer.

Use in high-risk groups and precautions

Mounjaro is considered a relatively safe drug, but careful judgment is needed before giving it to patients who fall into the following categories.

  • Patients with a history of pancreatitis
    It has been pointed out that GIP/GLP-1 receptor agonists may slightly increase the risk of pancreatitis.
  • Patients with severe kidney impairment
    If kidney function is reduced, there is a risk that symptoms will worsen through dehydration caused by vomiting or diarrhea.
  • Women who are pregnant or breastfeeding
    Because safety data are insufficient, it should in principle not be given.

Before starting treatment, a medical interview, proper assessment and explanation by a doctor are essential. During the consultation, the doctor carefully checks your medical history, other medications and any changes in your health, then decides whether the drug can be given and how the dose will be adjusted.

Future research and outlook

Research on Mounjaro is progressing mainly in Western countries, but the following challenges remain.

  1. Long-term cardiovascular risk assessment
    The SURMOUNT trial series reported good short- to medium-term safety, but long-term data over 10 years or more are still insufficient.
  2. Verifying effectiveness in Asian people
    Large clinical trials in Japanese and other Asian people are limited compared with Western populations, and differences in efficacy and side effects due to ethnicity need to be checked.
  3. Finding the best way to combine it with lifestyle improvements
    Establishing the best treatment protocol combining diet therapy, exercise therapy and psychological support is a future task.

Possible future clinical uses of Mounjaro

Going forward, its use in a wider range of settings, such as obesity prevention, weight loss before surgery and multi-drug therapy, is being explored.

  1. Use in obesity prevention
    There is discussion about whether short-term use of Mounjaro in people with a somewhat high BMI who have not yet developed obesity-related conditions might prevent obesity from progressing.
  2. Support for weight loss before surgery
    For patients who need to lose weight before surgery, Mounjaro may be considered as an adjunct therapy to promote weight loss.
  3. As part of multi-drug therapy
    Customized treatment tailored to each patient, using it together with existing diabetes medications, is being explored.

About self-pay treatment and off-label use

Self-pay treatment
Medical weight loss is self-pay treatment (paid in full by the patient) and is not covered by public health insurance.
Off-label use
Using medicines for weight management or weight loss may be off-label use, outside the indications approved in Japan.
Relief System for Adverse Drug Reactions
With off-label use, health damage such as a serious side effect may not be covered by Japan’s Relief System for Adverse Drug Reactions.
Individual differences and the doctor’s judgment
Effects and side effects vary from person to person. A doctor decides after a consultation whether you can use a medicine and which medicine and dose are appropriate. Please tell us in advance about any symptoms, chronic conditions or medicines you are taking.

FAQ

We have compiled questions we often receive during consultations in a Q&A format.

QIs Mounjaro a pill or an injection?
A

It is an injection. You inject it yourself once a week into the abdomen, thigh or upper arm using an injection pen. If you are looking for an oral obesity medication, we can also tell you about other options such as Rybelsus.

QHow much weight can I lose with Mounjaro?
A

In the SURMOUNT-1 trial, an average loss of around 20% of body weight was reported in the highest-dose group after 72 weeks of treatment. However, these are clinical trial data obtained together with lifestyle-improvement guidance; results vary greatly between individuals, and you will not necessarily get the same result.

QWhat is the difference between Mounjaro and Rybelsus?
A

Mounjaro is an injectable drug that acts on GIP/GLP-1 receptors, while Rybelsus is an oral medication that acts on GLP-1 receptors. Because they differ in the receptors they act on and how they are taken, we recommend choosing which suits you by talking with a doctor, taking into account your constitution, lifestyle and whether you feel uneasy about injections.

QI’m worried about side effects. How will they be handled?
A

Because gastrointestinal symptoms are common early in treatment, we start at a low dose and increase it step by step while checking how you feel. If nausea or abdominal bloating is strong, we try to ease it by adjusting how much and how you eat and the pace of dose escalation. If symptoms continue, please consult us early.

QIs Mounjaro covered by health insurance?
A

Prescriptions for treating type 2 diabetes may be covered by health insurance, but use for treating obesity without diabetes is self-pay treatment not covered by health insurance. You can find details on costs on our pricing page.

QWill I regain weight if I stop?
A

It has been reported that weight tends to return over time after stopping treatment. To limit weight regain, it is important to build diet management and exercise habits alongside treatment while you are still on it. Also decide when and how to stop together with your doctor, not on your own.

Summary

The SURMOUNT trial series has confirmed that Mounjaro, a GIP/GLP-1 receptor dual agonist given as a once-weekly self-injection, is highly effective for weight loss in patients with obesity. Gastrointestinal symptoms are the main side effects, but most are mild, and combining it with lifestyle improvements makes it easier to increase weight loss. Mounjaro can be one option, especially for patients who also have type 2 diabetes and for those who find it hard to manage their weight through lifestyle improvements alone. Because effects and side effects vary from person to person, do not start or stop it on your own; always use it under a doctor’s care. The accumulation of clinical data in Japan and evaluation of long-term safety are still awaited.

References and evidence

  1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial). N Engl J Med. 2022;387:205–216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
  2. Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2 trial). Lancet. 2023.
  3. Pharmaceuticals and Medical Devices Agency (PMDA): Mounjaro Subcutaneous Injection package insert information https://www.pmda.go.jp/

Medically reviewed by: Dr. Hiroko Oka (Chair, Medical Corporation Fukubikai / Certified Member, Japanese Society of Internal Medicine)

*This article is intended to provide general information, and effects and side effects vary from person to person. Mounjaro is a prescription drug prescribed as self-pay treatment (not covered by health insurance except for the treatment of type 2 diabetes). Always use it under a doctor’s examination and guidance.

Who to contact if you have side effects | When to seek care

If you have any of the following symptoms, do not wait and see on your own; contact us. GIP/GLP-1 receptor agonists, including Mounjaro, are known to cause side effects, mainly gastrointestinal symptoms. Most are mild, but serious ones occur in rare cases.

SymptomPossible causeWhat to do
Ongoing nausea or vomitingGastrointestinal symptoms; the most common side effectContact us if you remain unable to keep fluids down
Severe abdominal pain (pain that goes through to the back)Possible acute pancreatitisStop the medication immediately and seek medical care
Cold sweats, palpitations, intense hunger, or feeling confused or drowsyHypoglycemiaTake some sugar right away and contact us
Skin rash, difficulty breathing, or swelling of the face or throatAllergic reactionSeek medical care immediately

Contact: 0120-241-929 (9:00–18:00)
If your symptoms are severe outside these hours, please go to your nearest emergency medical facility.

Direct phone numbers for each clinic are listed on the clinic information page.

References

The information about medications in this article is based on the following official sources. For details on dosage, administration and side effects, always check the latest electronic package insert.
Pharmaceuticals and Medical Devices Agency (PMDA): “Mounjaro Subcutaneous Injection Ateos, electronic package insert”
PMDA: “Drug Guide for Patients: Mounjaro Subcutaneous Injection Ateos” (PDF)
Ministry of Health, Labour and Welfare: “Prevention of lifestyle-related diseases”

Using Mounjaro for purposes other than obesity disease is self-pay treatment and is not covered by public health insurance. Effects and side effects vary from person to person.

Reviewing doctor: Hiroko Oka
Reviewing doctor

Hiroko OkaDirector, Hiro Clinic Kawaguchi (physician)

Japanese Society of Internal Medicine Chairman, Medical Corporation Fukubikai / Certified Member, Japanese Society of Internal Medicine After graduating from Toho University School of Medicine in 1997, joined the Department of Internal Medicine at Keio University School of Medicine. Gained experience in internal medicine at university and general hospitals, and opened Hiro Clinic in 2008. About our medical review and editorial policy

You may also like

Back to all articles

Ask our AI chat AI chat